Coronavirus Disease 2019 (COVID-19)
Conditions
Keywords
Silver nanoparticles, SARS-CoV-2, COVID-19, Infection control
Brief summary
In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells. Subsequently, the investigators assessed the effects of mouthwash and nose rinse with ARGOVIT® silver nanoparticles (AgNPs), in the prevention of SARS-CoV-2 contagion in health workers consider as high-risk group of acquiring the infection in the General Tijuana Hospital, Mexico, a hospital for the exclusive recruitment of patients diagnosed with COVID-19.
Detailed description
SARS-CoV-2 infection in hospital areas is of a particular concern, since the close interaction between health care personnel and patients diagnosed with COVID-19, which allows virus to be easily spread between them and subsequently to their families and communities. Preventing SARS-CoV-2 infection among healthcare personnel is essential to reduce the frequency of infections and outbreaks during the pandemic. In a first step, silver nanoparticles (AgNPs) were tested in vitro to determine an inhibitory effect on SARS-CoV-2 infection in cultured cells. Subsequently, the investigators assess the effects of mouthwash and nose rinse with ARGOVIT® silver nanoparticles (AgNPs), in the prevention of SARS-CoV-2 contagion in health workers consider as high-risk group of acquiring the infection in the General Tijuana Hospital, Mexico, a hospital for the exclusive recruitment of patients diagnosed with COVID-19. The investigators present a prospective randomized study of 231 participants that was carried out for 9 weeks (during the declaration of a pandemic). The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution; the control group was instructed to do mouthwashes and nose rinse in a conventional way.
Interventions
DEVICEMouthwash and nose rinse with the AgNPs solution
The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers
DEVICEMouthwashes and nose rinse in a conventional way
The control group was instructed to do mouthwashes and nose rinse in a conventional way
Sponsors
Bionag SAPI de CV
General Hospital Tijuana
Cluster de Bioeconomia de Baja California, A.C
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Intervention model description
Eligible participants for the in vivo study were randomized using a computer generated block scheme and stratified according to duty position, work shifts and the area/department of the service at General Tijuana Hospital. Individuals from experimental group were provided with a 50 mL spray bottle containing AgNPs solution with 1 wt% concentration (0.6 mg/mL metallic silver). Participants were instructed to mix 4 to 6 spray shots (corresponding to volume \ 0.5 mL) of this solution with 20 mL of water and to gargle with obtained solution for 15 to 30 seconds at least 3 times a day, also nasal lavages on the inner part of the nasal alae and nasal passage with the same solution using a cotton swap twice a day. As a second option, participants were instructed to cover evenly the oral cavity with the direct 1 to 2 spray shots of solution without its previous dilution in water.
Eligibility
Sex/Gender
ALL
Age
20 Years to 73 Years
Healthy volunteers
Yes
Inclusion criteria
* Men and women health workers in the General Tijuana Hospital, Mexico who works in high-risk areas with direct contact with patients infected and diagnosed with COVID-19.
Exclusion criteria
* persons with history of hypersensitivity to silver (rashes and other contraindications), * a history of SARS-CoV-2 infection in the three months prior to the start of the study, any respiratory distress, * and refusal to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of SARS-CoV-2 infection in the experimental group. | 9 weeks | Percentage of participants infected of SARS-CoV-2 in the experimental group. |
| Incidence of SARS-CoV-2 infection in the control group. | 9 weeks | Percentage of participants infected of SARS-CoV-2 in the control group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse reactions by AgNPs. | 9 weeks | Number of participants with adverse reactions by performing mouthwash and nose rinse with AgNPs. |
Countries
Mexico
Outcome results
None listed